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Thymic stromal lymphopoietin (TSLP) is an interleukin (IL) 7–like cytokine that 
triggers dendritic cell–mediated T helper (Th)2 infl  ammatory responses. TSLP is 
highly expressed by keratinocytes in skin lesions of patients with atopic dermatitis 
and is associated with dendritic cell activation in situ, suggesting that TSLP might 
be a master switch for allergic infl  ammation at the epithelial cell–dendritic cell 
interface. New reports now establish a direct link between TSLP expression and 
the pathogenesis of atopic dermatitis and asthma in vivo, and begin to reveal the 
molecular mechanisms underlying TSLP-induced allergic infl  ammation.
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Thymic stromal lymphopoietin (TSLP) 
is a novel IL-7–like cytokine, origi  nally 
cloned from a murine thymic   stromal 
cell line, that supports the growth and 
diff  erentiation of  B cells and the prolifera-
tion of T cells (1, 2). The TLSP recep-
tor (TLSPR) is heterodimeric, consisting 
of the IL-7R–α chain and a common γ 
 receptor–like chain (TSLPR-γ) (3–6).
Human TSLP and TSLPR were 
cloned in 2001 by computational ana-
lyses of human genomic data (7, 8). 
The early human studies were initially 
frustrating because human recombinant 
TSLP (hTSLP), unlike mouse TSLP, 
did not support the development or 
  activation of B and T cells. Surprisingly, 
our group found that hTSLP instead 
potently activated immature CD11c+ 
myeloid dendritic cells (mDCs) (7, 9). 
TSLP-activated DCs induced robust 
proliferation of naive allogeneic CD4+ 
T cells, which subsequently diff  erentiated 
into Th2 cells that produced the allergy-
promoting cytokines IL-4, IL-5, IL-13, 
and TNF, but did not produce IL-10 
or interferon-γ (9).
In vivo, TSLP was shown to be 
highly expressed by keratinocytes in 
atopic dermatitis lesions and its expres-
s  ion was associated with the migration 
and activation of Langerhans cells, sug-
gesting for the fi   rst time that TSLP 
might be an early trigger for DC-medi-
ated allergic infl  ammation (9). Human 
TSLP was later found to be expressed 
by epithelial cells in peripheral mucosal-
associated lymphoid tissue, where it 
activates mDCs to induce homeostatic 
proliferation of naive and memory 
CD4+ T cells in the periphery (10, 
11). TSLP is also produced by Has-
sall’s corpuscles in the human thymus, 
where it instructs thymic DCs to con-
vert high affi     nity self-reactive T cells 
into CD4+CD25+Foxp3+ regulatory 
T cells (12).
In this commentary, we will review 
the recent progress in understanding 
the role of TSLP in the development 
of atopy and the underlying molecular 
mechanisms that govern this process.
TSLP-activated DCs create 
a Th2-permissive microenvironment
Like all stimuli that activate mDCs, 
including CD40L and Toll-like recep-
tor (TLR) ligands, such as bacterial li-
popolysaccharide (LPS), poly I:C, and 
R848, TSLP strongly up-regulates the 
expression of MHC class II, CD54, 
CD80, CD83, CD86, and DC-lamp 
on human mDCs. However,   unlike 
CD40L and TLR ligands, TSLP does 
not stimulate mDCs to produce the 
Th1-polarizing cytokine IL-12 or the 
proinfl  ammatory cytokines TNF, IL-1β, 
and IL-6 (9). Our recent gene expres-
sion analyses of TSLP-activated DCs 
confi   rm and extend this fi  nding  by 
showing that TSLP does not induce the 
expression of mRNA encoding the IL-
12 family members IL-12, IL-23, and 
IL-27, nor that of mRNA encoding 
the type I IFNs—all cytokines that in-
duce Th1 diff  erentiation (13). Interest-
ingly, TSLP treatment caused mDCs 
to produce large amounts of the chemo-
kines IL-8 and eotaxin-2, which attract 
neutrophils and eosinophils, as well as 
TARC and MDC, which attract Th2 
cells (unpublished data). We suggest 
that the inability of TSLP to induce the 
production of Th1-polarizing cytokines 
by mDCs is one of the most important 
features of TSLP-activated DCs, and 
helps these cells create a Th2- permissive 
microenvironment. The molecular me-
chanisms underlying TSLP’s ability to 
promote mDC maturation without in-
ducing the production of Th1-polar-
izing cytokines are unknown. TSLP 
appears to activate a unique   signaling 
pathway in mDCs that is independent 
of the transcription factor NF-κB and 
the TLR adaptor protein MyD88, 
both of which are required for the re-
sponse to Th1-promoting stimuli. This 
  hypothesis is supported by the fact that 
TSLP activates STAT5 in myeloid cells 
(7, 14) although the signaling molecules 
that function upstream and downstream 
of STAT5 in this pathway are currently 
unknown. In contrast, neither TLR 
ligands nor CD40L appear to activate 
STAT5 in mDCs.
TSLP-DCs induce infl  ammatory Th2 cells
In most immunology textbooks and lit-
erature, Th2 cells are defi  ned as CD4+ 
T cells that produce IL-4, IL-5, IL-13, 
and IL-10, and Th1 cells such as CD4+ 
T cells that produce IFN-γ and some-
times TNF. When TSLP-DCs are used 
to stimulate naive allogeneic CD4+ T 
cells in vitro, they induce a unique type 
of Th2 cell that produces the classical 
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the developing Th2 cells synergized 
with the OX40L-derived signals to fur-
ther promote Th2 cell   development. 
We thus conclude that TSLP-activated 
DCs create a Th2-  permissive microen-
vironment by up-regulating OX40L 
without inducing the production of 
Th1-polarizing cytokines. The domi-
nance of IL-12 over OX40L may pro-
vide a molecular explanation for the 
hygiene theory, which proposes that 
microbial infections that trigger Th1 
  responses may decrease the subsequent 
development of Th2-driven atopy.
The association of TSLP with atopic 
dermatitis and asthma
Early studies showed that TSLP mRNA 
was highly expressed by human primary 
skin keratinocytes, bronchial epithelial 
cells, smooth muscle cells, and lung fi  -
broblasts, but not by most hematopoi-
etic cells, including B cells, T cells, NK 
cells, granulocytes, macrophages, mono-
cytes, and DCs. Interestingly, mast cells 
and large amounts of TNF, but little 
or no IL-10 (9). Although not typi-
cally considered a Th2 cytokine, TNF 
is prominent in asthmatic airways, and 
genotypes that correlate with increased 
TNF secretion are associated with an 
increased risk of asthma (15, 16), sug-
gesting that TNF plays an important 
role in the development of asthma and 
allergic infl  ammation.
In addition to inducing the produc-
tion of Th2 cytokines and TNF, CD4+ 
T cells activated by TSLP-stimulated 
DCs produce decreased levels of IL-10 
and IFN-γ, two cytokines known to 
down-regulate Th2 cell infl  ammation 
(17). IL-10, although initially classifi  ed 
as a Th2 cytokine, counteracts infl  am-
mation and is produced at decreased 
levels in bronchoalveolar lavage fl  uid 
from atopic patients compared with 
normal subjects (18). In addition, recent 
studies showed that DC- or T cell–
  derived IL-10 prevents airway hypersen-
sitivity after allergen exposure (19, 20).
Because of their unique profi  le of 
cytokine production, we propose that 
Th2 cells induced by TSLP-activated 
DCs be called infl  ammatory Th2 cells. 
The pathogenic T cells involved in al-
lergic diseases such as atopic dermatitis 
and asthma are likely to be infl  amma-
tory Th2 cells. Conventional Th2 cells 
that produce IL-4, IL-5, IL-13, and 
IL-10, but little TNF may not be in-
volved in promoting allergic diseases 
but are induced in many circumstan-
ces, including when antigen-presenting 
cells or T cells are treated with im    muno  -
suppressive drugs, and when T cells are 
triggered by low affi   nity TCR ligands 
(21–23).
OX40 ligand promotes 
the differentiation of infl  ammatory 
Th2 cells
In an attempt to identify the molecular 
mechanism by which TSLP-activated 
DCs induce naive CD4+ T cells to dif-
ferentiate into TNF-producing infl  am-
matory Th2 cells, our group performed 
gene expression analysis on immature 
human mDCs that were either resting 
or were activated by TSLP, poly I:C, 
or CD40L. This analysis, reported in a 
  recent issue of JEM, showed that only 
TSLP induces human mDCs to express 
the TNF superfamily protein OX40L at 
both the mRNA and protein level (13).
The expression of OX40L by TSLP-
DCs was important for the induction 
of infl  ammatory Th2 cells, as blocking 
OX40L with a neutralizing antibody 
inhibited the production of Th2 cyto-
kines and TNF, and enhanced the pro-
duction of IL-10, by the CD4+ T cells. 
Consistent with these results, we found 
that treating naive T cells with recombi-
nant OX40L promoted the production 
of TNF but inhibited the production of 
IL-10. In other words, signals triggered 
by OX40L induced the generation of 
infl  ammatory Th2 cells.
OX40L-induced infl  ammatory Th2 
cell diff  erentiation depended on the ab-
sence of IL-12, as OX40L lost the ability 
to trigger infl  ammatory Th2 cell diff  er-
entiation in the presence of IL-12. The 
ability of OX40L to trigger Th2 cell de-
velopment was independent of IL-4, al-
though the IL-4 that was produced by 
Figure 1.  TSLP expression in atopic dermatitis associates with Langerhan’s cell migration 
and activation. Normal skin contains Langerin+ langerhan’s cells (blue) in the epidermis (a and c) 
and DC-lamp+ DCs (blue) in the epidermis and dermis (b and d). TSLP (red) is not expressed in normal 
skin (a and b). However, skin lesions from patients with atopic dermatitis express high levels of TSLP 
(c), which is associated with the migration of Langerhan’s cells from the epidermis to the dermis (d). 
Reprinted with permission from Nature Immunology (Soumelis V., P.A. Reche, H. Kanzler, W. Yuan, 
G. Edward, B. Homey, M. Gilliet, S. Ho, S. Antonenko, A. Lauerma, et al. 2002. Human epithelial cells 
trigger dendritic cell mediated allergic infl  ammation by producing TSLP. Nat. Immunol. 3:673–680.).COMMENTARY
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activated by IgE receptor cross-linking 
expressed high levels of TSLP, suggesting 
an additional cell type that may help 
trigger allergic infl  ammation. TSLP pro-
tein, examined by immunohistology on 
cryopreserved tissue sections, is unde-
tectable in normal skin or nonlesional 
skin in patients with atopic dermatitis, 
but is highly expressed in acute and 
chronic atopic dermatitis lesions (9). 
TSLP is expressed mainly in keratino-
cytes of the apical layers of the epider-
mis, suggesting that TSLP production is 
a feature of fully diff  erentiated keratino-
cytes (Fig. 1).  TSLP was not found in 
skin lesions from patients with nickel-
induced contact dermatitis or dissemi-
nated lupus erythematosus. Interestingly, 
TSLP expression in patients with atopic 
dermatitis was associated with Langer-
hans cell migration and activation in situ 
(Fig. 1), suggesting that TSLP may con-
tribute directly to the activation of these 
cells, which could then migrate into the 
draining lymph nodes and prime allergen-
specifi  c Th2 responses (9).
A more recent study showed by in 
situ hybridization that TSLP expression 
was increased in asthmatic airways and 
correlated with both the expression of 
Th2-attracting chemokines and with 
disease severity (24), providing the fi  rst 
link between TSLP and human asthma.
TSLP triggers atopic dermatitis 
and asthma in mice
Our own attempts to demonstrate the 
function of TSLP in mice were unsuc-
cessful, leading us to believe that TSLP 
may function diff  erently in humans and 
mice. But reports from three laborato-
ries now reveal that TSLP and TSLPR 
also play a critical role in the initiation of 
allergic diseases in mice.
In a recent issue of JEM, Yoo et al. 
demonstrated that mice engineered to 
overexpress TSLP in the skin developed 
atopic dermatitis characterized by ec-
zematous skin lesions containing infl  am-
matory cell infi  ltrates, a dramatic increase 
in circulating Th2 cells and elevated se-
rum IgE (25). This study also suggested 
that TSLP may directly activate DCs in 
mice. In another study, Li et al. reported 
the surprising fi  nding that selective abla-
tion of retinoid X receptors (RXRs) in 
epidermal keratinocytes triggered atopic 
dermatitis in mice (26). The authors of 
that study noted that TSLP expression 
was rapidly induced in skin keritinocytes 
that lacked RXRs, likely contributing to 
the development of disease. This group 
confi   rmed the fi   nding that transgenic 
mice overexpressing TSLP in the skin 
developed atopic dermatitis, thus solidi-
fying the link between TSLP and the 
development of atopic dermatitis.
Two recent studies also formally es-
tablished a critical role of TSLP in the 
initiation of asthma in vivo. Zhou et al. 
showed that lung-specifi  c  expression 
of a TSLP transgene induced allergic 
airway infl  ammation (asthma) charac-
terized by a massive infi  ltration of leu-
kocytes (including Th2 cells), goblet cell 
hyperplasia, and subepithelial fi  brosis, as 
well as increased serum IgE levels (27). 
In contrast, mice lacking TSLPR failed 
to develop asthma in response to inhaled 
antigens (27, 28). Together, these stud-
ies demonstrate that TSLP is required 
for the initiation of allergic airway in-
fl  ammation in mice.
Conclusion and future perspective
We now know that TSLP is highly ex-
pressed by skin keratinocytes and airway 
epithelial cells during allergic infl  amma-
tion (Fig. 2), but how TSLP expression 
is triggered in these cells—by allergen 
exposure or virus infection—remains 
unclear. As the expression of RXRs in 
skin keratinocytes may actively suppress 
TSLP production under normal physio-
logical conditions, further studies on the 
regulation of these receptors may provide 
important clues as to how allergen or vi-
ral infection triggers TSLP production.
TSLP instructs mDCs to induce in-
fl  ammatory Th2 cells in two ways (Fig. 
2). First, TSLP induces DC maturation 
without driving the production of the 
Th1-polarizing cytokine IL-12, thus 
creating a Th2-permissive microenviron-
ment. Second, TSLP induces the expres-
sion of OX40L on DCs, which directly 
Figure 2.  Pathophysiology of TSLP in allergic infl  ammation. Insults from allergens or viruses 
trigger mucosal epithelial cells or skin cells (keratinocytes, fi  broblasts, and mast cells) to produce 
TSLP (step 1). TSLP activates immature DCs (step 2). TSLP-activated DCs produce the chemokines IL-8 
and eotaxin-2, which attract neutrophils and eosinophils, as well as TARC and MDC, which attract 
Th2 cells (step 3). TSLP-activated mDCs mature and migrate into the draining lymph nodes (step 4). 
TSLP-activated DCs also express OX40L, which triggers the differentiation of allergen-specifi  c naive 
CD4+ T cells to infl  ammatory Th2 cells that produce IL-4, IL-5, IL-13, and TNF but not IL-10 (step 5). 
Infl  ammatory Th2 cells then migrate back to the site of infl  ammation because of the local produc-
tion of TARC and MDC (step 6). The Th2 cytokines IL-4, IL-5, IL-13, and TNF, produced by the infl  am-
matory Th2 cells, initiate allergic infl  ammation by triggering IgE production, eosinophilia, and mucus 
production (step 7).272   THYMIC STROMAL LYMPHOPOIETIN IN ALLERGY | Liu
triggers the diff  erentiation of infl  amma-
tory Th2 cells. The signaling pathway 
that is triggered by TSLP and leads to 
this unique Th2 phenotype is unknown, 
but it appears to involve STAT5 activa-
tion, independent of the classical NF-κB 
and myD88 signaling pathways.
OX40L signaling has several impor-
tant features. It triggers Th2 polarization 
independent of IL-4, promotes TNF 
production, and inhibits IL-10 produc-
tion by the developing Th2 cells, but 
only in the absence of IL-12. In the pres-
ence of IL-12, OX40L signaling instead 
promotes the development of Th1 cells 
that, like infl   ammatory Th2 cells, pro-
duce TNF, but not IL-10. This fi  nding 
may help explain why blocking OX40–
OX40L interaction reduces the severity 
of Th1-mediated autoimmune diseases 
(29)—the reason some immunologists 
are reluctant to accept OX40L as a Th2 
polarizing factor. We now believe that 
this inhibition of Th1-induced pathol-
ogy is caused by the increased produc-
tion of the immunosuppressive cytokine 
IL-10 and the decreased production of 
the infl  ammation-promoting  cytokine 
TNF that results from blocking OX40–
OX40L interactions.
Based on these recent studies, we pro-
pose the subdivision of Th2 cells into in-
fl  ammatory Th2 cells that produce high 
levels of TNF but little IL-10, and conven-
tional Th2 cells that produce little TNF 
but high levels of IL-10. Infl  ammatory 
Th2 cells, but not conventional Th2 cells, 
may be involved in allergic infl  ammatory 
diseases.
Our initial fi   nding that epithelial 
cell–derived TSLP triggers DC-mediated 
infl  ammatory Th2 responses in humans, 
together with the exiting in vivo studies 
reported in the last few months, suggest 
that TSLP represents a master switch of 
allergic infl   ammation at the epithelial 
cell–DC interface. TSLP should there-
fore be considered as a target for immu-
nological intervention in the treatment 
of allergic diseases.
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